FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
137 -
PO-67 | Investigating plasma neurofilament light chain levels in patients with migraine: a cross-sectional study Elisa Maria Piella,1 Alberto Mario Chiarandon,1 Silvia Boschi,1 Fausto Roveta,1 Lucrezia Bonino,1 Giulia Gioiello,2 Giulia Montesano,2 Giulio Mengozzi,2 Innocenzo Rainero,1,3 Elisa Rubino1,3 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Clinical Biochemistry Laboratory “Baldi e Riberi”, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy; 3Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, Italy
133 -
PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine Laura Marino,1 Marta Lioi1, Rosario Iannacchero,2 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
243 -
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
273 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
213 -
OC-14 | Efficacy of eptinezumab during a migraine attack: preliminary data from an Italian multicenter real-world experience (the BEFREE study) Luisa Fofi,1 Claudia Altamura,1 Marilena Marcosano,1 Alberto Doretti,2 Francesca Pistoia,3 Antonio Granato,4 Simona Guerzoni,5 Michele Trimboli,6 Licia Grazzi,7 Danilo Antonio Montisano,7 Gianluca Avino,8 Gabriele Sebastianelli,9 Carla Fasano,10 Elisa Maria Piella,11 Nicoletta Brunelli,1 Luigi Francesco Iannone,5,12 Fabrizio Vernieri1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Neurosonology and Headache Unit, Fondazione Policlinico Campus Bio-Medico, Rome; 2IRCCS Istituto Auxologico Italiano - Department of Neurology and Laboratory of Neuroscience - Milan; 3University of L’Aquila; 4Headache Center, Neurology Clinic, University of Trieste, University Hospital of Trieste; 5AOU Policlinico di Modena; 6Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 7Headache Center, Neuroalgology Dpt, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan; 8SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato; 9La Sapienza University of Rome Polo Pontino, Latina; 10Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence; 11Department of Neuroscience “Rita Levi Montalcini”, University of Turin; 12Università di Modena e Reggio Emilia, Italy
255 -
OC-17 | Profiling miR-30a expression in patients with episodic and chronic migraine Elisa Rubino,1,2 Elisa Maria Piella,1 Giulia Cicilese,1,3 Silvia Boschi,1 Alberto Mario Chiarandon,1 Elena Tamagno,1,3 Michela Guglielmotto,1,3 Innocenzo Rainero1,2 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino; 3Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano (TO), Italy
97 -
PO-47 | Systemic ozone treatment in chronic migraine: a focus on disability reduction and medication use Sergio Sorrenti,1,2 Matteo Ciuffreda,1 Emanuele Pisello,1 Luca Brugiaferri,2 Azzurra Federici,2 Cristiano Piangatelli,3 Dario Galante4 | 1U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 2Scuola di Specializzazione in Anestesia Rianimazione, Terapia Intensiva e del Dolore, UNIVPM, Ancona, Italy; 3Direttore U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 4Direttore U.O.C. Anestesia e Rianimazione, Cerignola (FG), Italy
133 -
PO-88 | Can tamoxifen and metformin nullify efficacy of CGRP-mAbs migraine prophylaxis? Patrizia Rossi,1,2 Valentina Cima,2 Alessandro Burlina2 | 1Headache Center, 2Neurology Department, San Bassiano Hospital, Bassano del Grappa (VI), Italy
298 -
PO-24 | Inflammatory signatures of comorbid episodic migraine and endometriosis: a cytokine-based analysis Maria Albanese,1,2 Veronica Ceci,3,4 Giulia Carrera,4,5 Aikaterini Selntigia,6 Caterina Exacoustos,6 Marta Tiberi,4 Stefano Saracini,3,4 Alessandro Matteocci,4,7 Nicola Biagio Mercuri,1,2,8 Valerio Chiurchiù3,4 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome; 3Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome; 4Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, Rome; 5PhD Program in Neuroscience, Department of Systems Medicine, University of Rome Tor Vergata, Rome; 6Department of Surgical Sciences, Gynecological Unit, University of Rome Tor Vergata, Rome; 7PhD program in Immunology, Molecular Medicine and Applied biotechnologies, University of Rome Tor Vergata, Rome; 9Laboratory of Experimental Neuroscience, IRCCS Santa Lucia Foundation, Rome, Italy
158 -
PO-51 | Rimegepant combined with valproic acid and botulinum toxin in refractory hemiplegic migraine: a case report Gianni Difonzo, Cinzia Tamborino, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy
161 -
PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
200 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
214 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
228 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
304 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
136 -
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
182 -
PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
109 -
PO-30 | A chronic migraine phenotype unveiling acromegaly: diagnostic pitfalls and the impact of timely treatment Cinzia Rita Tamborino, Gianni Difonzo, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy
226 -
PO-25 | Antiepileptic medication in PRRT2 familial hemiplegic migraine: a case report L. Bartole, A. Granato, G. Garascia, P. Manganotti | Clinical Unit of Neurology, Headache Centre, Department of Medicine, Surgery and Health Sciences, University of Trieste, Italy
202 -
PO-46 | Diagnostic tests and headache misdiagnoses in individuals with resistant and refractory migraine – data from the REFINE study Federico De Santis,1 Chiara Rosignoli,1 Agnese Onofri,1 Mark Braschinsky,2 Olga Sved,2 Raquel Gil-Gouveia,3,4 Renato Oliveira,3 Christian Lampl,5 Jakob Paungarttner,5 Paolo Martelletti,6 William David Wells-Gatnik,7 Isabel Pavao Martins,8 Dimos D Mitsikostas,9 Loukia Apostolakopoulou,9 Aynur Ozge,10 Dilan Bayar Narin,10 Patricia Pozo-Rosich,11 Albert Munoz-Vendrell,11 Maria Pia Prudenzano,12 Martino Gentile,12 Kristina Ryliskiene,13 Jurgita Vainauskiene,14 Margarita Sanchez-del-Rio,15 Fabrizio Vernieri,16 Gianmarco Iaccarino,16 Marta Waliszewska-Prosół,17 Sławomir Budrewicz,17 Marta Carnovali,18 Zaza Katsarava,18 Simona Sacco,1 Raffaele Ornello1 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 2Department of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, University of Tartu and Neurology Clinic of Tartu University Hospital, Tartu, Estonia; 3Headache Center, Neurology Department, Hospital da Luz, Lisboa, Portugal; 4Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa; 5Headache Medical Center, Seilerstaette Linz, Linz, Austria; 6Unitelma Sapienza University of Rome, Italy; 7Texas Tech University Health Sciences Center, El Paso TX, USA; 8Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; 9First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece; 10Department of Neurology, Mersin University Medical Faculty, Mersin, Turkey and NOROM Neuroscience and Neurotechnology Center of Excellence, Ankara, Turkey; 11Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Headache and Neurological Pain Research Group, VHIR, Barcelona, Spain; 12Headache Center, “I. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy; 13Center of Neurology, Vilnius University, Vilnius, Lithuania; 14Center of Neurology, Kardiolitos klinikos, Vilnius, Lithuania; 15Department of Neurology, Clínica Universidad de Navarra, Madrid, Spain; 16Unit of Headache and Neurosonology, Fondazione Policlinico Campus Bio-Medico and Neurology, Università Campus Bio-Medico di Roma, Roma, Italy; 17Department of Neurology, Wroclaw Medical University, Wrocław, Poland; 18Department of Neurology, Christian Hospital Unna and University of Duisburg-Essen, Ruhr Metropolitan, Germany
103 -
PO-61 | Social cognition in interictal episodic and chronic migraine: a cross-sectional study Chiara Abbatantuono,1* Delussi Marianna,2* Clemente Livio,1 Giulia Paparella,1 Stefania Scannicchio,1 Annalisa Di Dio,1 Elena Ammendola,1 Giusy Tancredi,1 Emmanuella Ladisa,1 Giulia Paparella,1,3 Marina de Tommaso1 (*Equally Contributed) | 1Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro (IT), Bari, Italy; 2Department of Education, Psychology, Communication (For.Psi.Com.), University of Bari Aldo Moro (IT), Bari, Italy; 3IRCCS Neuromed Pozzilli (IS), Italy
103 -
PO-85 | Alterations in gut microbiota and the endocannabinoid system in an animal model of chronic migraine Sara Facchetti,1,2 Chiara Demartini,1 Miriam Francavilla,1,2 Rosaria Greco,1 Cristina Tassorelli1,2 | 1Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
249 -
PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy
195 -
PO-81 | Knowledge and misconceptions on headache disorders among healthcare workers: preliminary results from the Studio Emicrania Maugeri Study Luca Giani, Christian Lunetta | Istituti Clinici Scientifici Maugeri IRCCS, Neurological Rehabilitation Unit of Milano Institute, Milan, Italy
214 -
PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy
186 -
PO-76 | Atogepant reduces psychological dependence to acute treatments evaluated with the Leeds dependence questionnaire (LDQ): a prospective observational study Luigi Francesco Iannone,1,2 Marina Romozzi,3,4 Alberto Boccalini,1 Flavia Lo Castro,1 Claudia Altamura,5 Fabrizio Vernieri,5 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
227 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
107 -
OC-04 | The chronopharmacology of atogepant in migraine prevention: a real-world evaluation of influence of timing of administration on effectiveness and tolerability Luigi Francesco Iannone,1,2 Gabriele Sebastianelli,3 Flavia Lo Castro,2 Federico De Santis,4 Michele Corrado,5 Marilena Marcosano,6,7 Raffaele Ornello,4 Licia Grazzi,8 Danilo Antonio Montisano,8 Francesco De Cesaris,9 Antonio Munafò,9 Gianluca Avino,10 Michele Trimboli,11 Maria Albanese,12 Antonio Russo,13 Giorgio Dalla Volta,14 Marina Romozzi,15 Paola Merlo,16 Luisa Fofi,6,7 Alberto Doretti,17 Gloria Vaghi,5 Francesca Pistoia,4 Delfina Ferrandi,18 Stefania Battistini,19 Gianluca Coppola,3 Simona Sacco,4 Simona Guerzoni,2 Claudia Altamura,6,7 Fabrizio Vernieri,6,7 On behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia; 2Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 5Department of Brain and Behavioral Sciences, University of Pavia; Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 6Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 7Neurology Unit, Università Campus Bio-Medico di Roma; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache center and Clinical Pharmacology, AOU Careggi, Florence; 10SOC Neurologia, Ospedale di Prato; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 12Università Roma Tor Vergata, Roma; 13Università della Campania "Luigi Vanvitelli", Napoli; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo; 17Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano; 18Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy
113 -
PO-28 | Sex differences in the response to rimegepant for the treatment of acute migraine attacks – insights from the multicenter GAINER study Raffaele Ornello,1 Gloria Vaghi,2,3 Gabriele Sebastianelli,4 Francesco Casillo,4 Antonio Russo,5 Marcello Silvestro,5 Francesca Pistoia,1 Giorgio Dalla Volta,6 Matteo Cortinovis,6 Alberto Chiarugi,7 Danilo Antonio Montisano,8 Licia Grazzi,8 Maria Pia Prudenzano,9 Sabina Cevoli,10 Edoardo Mampreso,11 Gianluca Avino,12 Marina Romozzi,13 Mariarosaria Valente,14 Carla Fasano,15 Stefania Battistini,16 Antonio Granato,17 Elisa Maria Piella,18 Innocenzo Rainero,18 Federico De Santis,1 Simona Sacco,1 Maria Albanese,19 Michele Trimboli,20 Alberto Doretti,21 Cristina Tassorelli,2,3 Luigi Francesco Iannone,22 Roberto De Icco2,3 on behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Brain and Behavioral Sciences, University of Pavia; 3Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 4Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 5Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples; 6Headache Center of Clinical Neurology of Istituto Clinico "Città di Brescia", Brescia; 7Department of Health Sciences, University of Florence; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari; 10IRCCS Istituto Di Scienze Neurologiche di Bologna, Programma Cefalee e Algie Facciali, Bologna; 11Headache Centre, Neurology - Euganea, Health Unit, Padua; 12Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato; 13Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome; 14Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale, Presidio Ospedaliero Santa Maria della Misericordia, Udine; 15Headache and Facial Pain Center Neurology, AOU Careggi, Florence; 16Department of Medical, Surgical and Neurological Sciences, University of Siena; 17Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste; 18Department of Neurosciences “Rita Levi Montalcini”, University of Turin; 19Department of Systems Medicine, University of Rome Tor Vergata, Rome; 20University Magna Graecia, Catanzaro; 21Department of Neuroscience - Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan; 22University of Modena and Reggio Emilia, Modena, Italy
245 -
PO-39 | Leeds Dependence Questionnaire (LDQ) in migraine: diagnostic utility without predictive value for anti-CGRP (R) response Antonio Munafò,1 Andrea Burgalassi,1 Giulia Vigani,2 Francesco De Cesaris,1 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
194 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
208 -
PO-14 | Pain catastrophizing in chronic migraine patients receiving eptinezumab treatment Alessandra Parisi,1 Licia Grazzi,1 Alberto Raggi,2 Giulia Regonesi,1 Montisano Danilo Antonio1 | 1Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano; 2Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
227